| Literature DB >> 33708738 |
Fatemeh Shahbazi1, Davood Mirtorabi2, Mohammad Reza Ghadirzadeh3, Ahmad Shojaei3, Seyed Saeed Hashemi Nazari4.
Abstract
BACKGROUND: Using dexmedetomidine (Dex) as a sedative agent may benefit the clinical outcomes of post-surgery patients. We reviewed randomized controlled trials (RCTs) to assess whether use of a Dex could improve the outcomes in post-surgery critically ill adults.Entities:
Keywords: Delirium; Dexmedetomidine; Mechanical ventilation; Sedation
Year: 2020 PMID: 33708738 PMCID: PMC7917516 DOI: 10.18502/ijph.v49i11.4735
Source DB: PubMed Journal: Iran J Public Health ISSN: 2251-6085 Impact factor: 1.429
Number and rates per 100,000 people of opioid related death by year and age groups over the four-year period from 2014 to 2017 in Iran
| Males | |||||||||
| Under 4 | 22 | 0.66 | 14 | 0.42 | 22 | 0.62 | 17 | 0.48 | |
| 5 to 14 | 12 | 0.21 | 10 | 0.16 | 13 | 0.21 | 19 | 0.30 | |
| 15 to 29 | 694 | 6.21 | 680 | 6.28 | 768 | 7.32 | 786 | 7.73 | |
| 30 to 44 | 1313 | 13.74 | 1399 | 14.08 | 1248 | 12.09 | 1369 | 12.77 | |
| 45 to 59 | 542 | 9.87 | 512 | 9.00 | 497 | 8.44 | 555 | 9.10 | |
| 60 to 69 | 99 | 5.74 | 76 | 4.16 | 87 | 4.49 | 124 | 6.04 | |
| 70 to 79 | 26 | 2.51 | 30 | 2.93 | 30 | 2.92 | 37 | 3.65 | |
| ≥ 80 | 10 | 1.96 | 7 | 1.38 | 5 | 0.95 | 14 | 2.38 | |
| All ages | 2718 | 7.01 | 2728 | 6.94 | 2671 | 6.70 | 292 | 7.22 | |
| Females | |||||||||
| Under 4 | 14 | 0.51 | 4 | 0.11 | 10 | 0.31 | 12 | 0.36 | |
| 5 to 14 | 14 | 0.23 | 10 | 0.17 | 7 | 0.11 | 15 | 0.25 | |
| 15 to 29 | 76 | 0.62 | 88 | 0.83 | 120 | 1.17 | 131 | 1.32 | |
| 30 to 44 | 97 | 1.36 | 106 | 1.10 | 131 | 1.31 | 133 | 1.28 | |
| 45 to 59 | 27 | 0.67 | 33 | 0.58 | 55 | 0.94 | 40 | 0.66 | |
| 60 to 69 | 5 | 0.38 | 12 | 0.61 | 5 | 0.25 | 10 | 0.45 | |
| 70 to 79 | 4 | 0.44 | 5 | 0.47 | 1 | 0.13 | 5 | 0.48 | |
| ≥ 80 | 2 | 0.79 | 1 | 0.24 | 3 | 0.51 | 1 | 0.24 | |
| All ages | 239 | 0.69 | 258 | 0.67 | 332 | 0.85 | 347 | 0.88 | |
| Total | |||||||||
| Under 4 | 36 | 0.59 | 18 | 0.27 | 33 | 0.47 | 30 | 0.42 | |
| 5 to 14 | 26 | 0.22 | 19 | 0.16 | 20 | 0.16 | 34 | 0.28 | |
| 15 to 29 | 770 | 3.27 | 768 | 3.58 | 888 | 4.28 | 916 | 4.57 | |
| 30 to 44 | 1411 | 8.45 | 1505 | 7.68 | 1380 | 6.78 | 1503 | 7.10 | |
| 45 to 59 | 569 | 5.95 | 544 | 4.81 | 552 | 4.71 | 595 | 4.91 | |
| 60 to 69 | 104 | 3.42 | 88 | 2.32 | 92 | 2.30 | 134 | 3.16 | |
| 70 to 79 | 30 | 1.58 | 35 | 1.70 | 31 | 1.51 | 42 | 2.05 | |
| ≥ 80 | 12 | 1.52 | 8 | 0.83 | 8 | 0.74 | 15 | 1.36 | |
| All ages | 2957 | 4.03 | 2986 | 3.84 | 3003 | 3.81 | 3269 | 4.09 | |
rates are presented per 100,000 population
YLL rates (YLL) per 1000 persons and absolute number of YLL (YLLs) by age groups and sex over the four-year period from 2014 to 2017 in Iran
| Males | |||||||||
| Under 4 | 1863 | 0.55 | 1211 | 0.35 | 1850 | 0.52 | 1422 | 0.39 | |
| 5 to 14 | 947 | 0.16 | 728 | 0.12 | 991 | 0.16 | 1360 | 0.22 | |
| 15 to 29 | 42288 | 3.79 | 41508 | 3.84 | 47027 | 4.48 | 47976 | 4.72 | |
| 30 to 44 | 64960 | 6.79 | 68797 | 6.93 | 61394 | 5.95 | 66948 | 6.24 | |
| 45 to 59 | 19245 | 3.50 | 18206 | 3.20 | 17920 | 3.04 | 20581 | 3.37 | |
| 60 to 69 | 2414 | 1.40 | 1819 | 1.00 | 2076 | 1.07 | 2923 | 1.42 | |
| 70 to 79 | 388 | 0.38 | 460 | 0.45 | 448 | 0.44 | 585 | 0.57 | |
| ≥ 80 | 83 | 0.17 | 59 | 0.11 | 39 | 0.07 | 84 | 0.15 | |
| All ages | 132188 | 3.41 | 132788 | 3.38 | 131745 | 3.30 | 141879 | 3.50 | |
| Females | |||||||||
| Under 4 | 1142 | 0.43 | 303 | 0.09 | 871 | 0.26 | 1004 | 0.29 | |
| 5 to 14 | 1050 | 0.18 | 737 | 0.13 | 500 | 0.09 | 1137 | 0.19 | |
| 15 to 29 | 4802 | 0.39 | 5549 | 0.52 | 7465 | 0.73 | 8038 | 0.81 | |
| 30 to 44 | 4801 | 0.67 | 5161 | 0.53 | 6562 | 0.65 | 6594 | 0.63 | |
| 45 to 59 | 944 | 0.23 | 1173 | 0.21 | 1910 | 0.33 | 1417 | 0.24 | |
| 60 to 69 | 114 | 0.09 | 286 | 0.14 | 132 | 0.06 | 228 | 0.10 | |
| 70 to 79 | 57 | 0.07 | 76 | 0.07 | 22 | 0.02 | 84 | 0.08 | |
| ≥ 80 | 18 | 0.06 | 11 | 0.02 | 19 | 0.04 | 9 | 0.02 | |
| All ages | 12928 | 0.37 | 13295 | 0.35 | 17480 | 0.45 | 18511 | 0.47 | |
| Total | |||||||||
| Under 4 | 3005 | 0.50 | 1514 | 0.22 | 2721 | 0.39 | 2426 | 0.34 | |
| 5 to 14 | 1997 | 0.17 | 1465 | 0.12 | 1491 | 0.12 | 2497 | 0.21 | |
| 15 to 29 | 47090 | 2.00 | 47057 | 2.20 | 54492 | 2.63 | 56014 | 2.79 | |
| 30 to 44 | 69761 | 4.18 | 73958 | 3.78 | 67956 | 3.34 | 73542 | 3.48 | |
| 45 to 59 | 20189 | 2.11 | 2992 | 1.71 | 19830 | 1.69 | 21998 | 1.82 | |
| 60 to 69 | 2528 | 0.83 | 2105 | 0.55 | 2208 | 0.55 | 3151 | 0.74 | |
| 70 to 79 | 445 | 0.24 | 536 | 0.26 | 470 | 0.23 | 669 | 0.32 | |
| ≥ 80 | 101 | 0.12 | 70 | 0.07 | 58 | 0.05 | 93 | 0.09 | |
| All ages | 145116 | 1.98 | 146083 | 1.88 | 149225 | 1.89 | 160390 | 2.01 | |
Fig. 1:The total YLLs for drug abuse by sex and provinces of the country during the 4-year study period
Fig. 2:Estimates of age-adjusted mortality rate due to opiate and psychotropic abuse in each province of residence in four years study from 2014 to 2017 in Iran
YLL rates (YLL) and YLL per 1000 persons (YLLs) by type of drug used over the four-year period from 2014 to 2017 in Iran
| YLLs | YLL | YLLs | YLL | YLLs | YLL | YLLs | YLL | |
| Opium | 37151 | 0.51 | 60061 | 0.76 | 45930 | 0.58 | 52929 | 0.66 |
| Heroin | 17420 | 0.23 | 30097 | 0.38 | 22500 | 0.29 | 25662 | 0.32 |
| Crack | 9299 | 0.13 | 47802 | 0.60 | 7465 | 0.09 | 24059 | 0.30 |
| Crystal | 17455 | 0.25 | 1883 | 0.03 | 28565 | 0.36 | 17643 | 0.22 |
| Alcohol | 551 | 0.02 | 1449 | 0.01 | 2191 | 0.04 | 1604 | 0.02 |
| Other | 63240 | 0.84 | 4791 | 0.06 | 42575 | 0.54 | 38494 | 0.50 |